ArticleHuman vaccines & immunotherapeutics2026
Cost-effectiveness of pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma.
Kexin Yu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.